| Promacta |
TPO Receptor AgonistPromacta is an FDA-approved treatment for chronic ITP in adults who have had an insufficient response to corticosteroids, immunoglobulins or surgical removal of the spleen. Promacta is authorized for use in all 27 member states of the European Union, as well as India, Australia, Ireland, Japan, Taiwan, Turkey, Singapore, Kuwait, Chile, Russia and Bahrain under the trade name RevoladeŽ. Promacta was co-discovered by Ligand and GSK.
Partner: GSK |
ITP |
GSK |
Marketed |
| Avinza |
ER- MorphineAvinza is an FDA-approved extended-release morphine treatment. Ligand currently receives a royalty on all sales.
Partner: Pfizer |
Pain |
Pfizer |
Marketed |
| Nexterone |
Captisol- enabled Amiodarone |
Arrhythmia |
Baxter |
Marketed |
| Viviant |
SERMViviant is a selective estrogen receptor modulator (SERM) used for the treatment of osteoporosis. Ligand receives royalties on sales of Viviant that Pfizer sells in the EU (branded as Conbriza in the EU).
Ligand receives royalties on sales of a SERM (selective estrogen receptor modulator) product called Viviant that Pfizer sells in the EU (called Conbriza in the EU). Viviant is used to treat osteoporosis.
Partner: Pfizer |
Osteoporosis |
Pfizer |
Marketed |
| Cerenia |
Captisol- enabled Canine Anti-NauseaCerenia is an FDA-approved anti-emetic developed specifically for dogs.
Partner: Pfizer |
Animal Health |
Pfizer |
Marketed |
| VFEND |
Captisol- enabled IV- VoraconazoleVfend is an FDA-approved drug for the treatment of candidemia in nonneutropenic patients and the following Candida infections: disseminated (deep tissue) infections in skin and infections in abdomen, kidney, bladder wall, and wounds.
Partner: Pfizer |
Antifungal |
Pfizer |
Marketed |
| Abilify-IM |
Captisol- enabled IM- AripiprazoleAbilify is an FDA-approved treatment for symptoms in psychotic conditions such as schizophrenia and bipolar disorder (manic depression).
Partner: BMS |
Schizophrenia |
BMS |
Marketed |
| Geodon |
Captisol- enabled IV- ZiprasidoneGeodon is an FDA-approved treatment for acute manic or mixed episodes associated with bipolar disorder.
Partner: Pfizer |
Schizophrenia |
Pfizer |
Marketed |
| Fablyn |
SERM |
Osteoporosis |
Chiva |
NDA |
| Kyprolis |
Captisol-enabled CarfilzomibKyprolis is a selective next-generation proteasome inhibitor with a mechanism of action aimed at increasing therapeutic efficacy and limiting the side effects associated with currently available therapies. |
Oncology |
Onyx |
Phase 3 |
| Carbamazepine- IV |
Captiol- enabled carbamazepine |
CNS |
Lundbeck |
Phase 3 |
| Undisclosed Captisol Program |
Undisclosed |
Undisclosed |
Merck |
Phase 3 |
| Promacta |
TPO Receptor AgonistPromacta is being developed for the treatment of patients with hepatitis C-related thrombocytopenia. Promacta was co-discovered by Ligand and GSK. |
HepC |
GSK |
P3 |
| Aprela |
SERM + PremarinAprela, bazedoxifene + Premarin(R) is a SERM (selective estrogen receptor modulator) discovered at Ligand. Aprela is being developed for the treatment of postmenopausal osteoporosis. |
Menopause |
Pfizer |
P3 |
| Clopidogrel IV |
Captisol- enabled ClopidogrelCaptisol -enabled Clopidogrel is being developed in IV solution. Clopidogrel is the active ingredient in Plavix(R), the world's leading anti-platelet medication which is currently only available in an oral formulation. Ligand is entitled to royalties on annual worldwide sales net. |
Anti- arrhythmia |
MDCO |
P2 |
| Promacta |
TPO Receptor Agonist |
Oncology |
GSK |
P2 |
| Dinaciclib |
CDK InhibitorA CXCR2 (chemokine receptor 2) inhibitor is being developed for the treatment of COPD. The compound was discovered at Ligand. |
Oncology |
Merck |
P2 |
| Tanzisertib |
JNK InhibitorJNK (Jun Kinase) inhibitor, Tanzisertib (CC-930) is currently being developed for the treatment of idiopathic pulmonary fibrosis. |
Pulmonary Fibrosis |
Celgene |
P2 |
| Tanaproget |
Progesterone Receptor AntagonistCTanaproget is a tissue-selective, non-steroidal contraceptive progesterone receptor agonist that has the potential for an improved side-effect profile over current steroidcontaining contraceptives. Pfizer granted a sublicense to a multi-national pharmaceutical company for Tanaproget. Ligand is entitled to additional payments based on clinical and regulatory milestones, along with royalties on future sales. |
Contraceptive |
Undisclosed |
P2 |
| GSK2285921 |
TPO Receptor AgonistGSK 2285921 is a follow-on compound to Promacta, an agonist of the thrombopoietin (TPO) receptor. GSK 2285921 was discovered at Ligand. |
ITP |
GSK |
P2 |
| Delafloxacin |
FluoroquinoloneFluoroquinolone |
Infection |
Rib-X |
P2 |
| Pradefovir |
HepDirect HepB InhibitorPradefovir is being developed in China for the treatment of HepB. |
HepB |
Chiva |
P1 |
| MB07133 (HCC) |
HepDirect HepB InhibitorMB07133 is being developed in China for the treatment of hepatocellular carcinoma. |
HCC |
Chiva |
P1 |
| XL652 |
LXR AgonistAn LXR (Liver X Receptor) agonist (XL652) is being developed in collaboration with Bristol-Myers Squibb for dyslipidemia and atheroclerosis that was based on technology that Ligand licensed to Exelixis. |
Atherosclerosis |
Exelixis |
P1 |
| XL550 |
MR AntagonistA MR (Mineralocorticoid Receptor) antagonist (XL550) is in collaboration with Daiichi Sankyo that was based on technology that Ligand licensed to Exelixis. The drug is in development for a variety of conditions, including diabetes, hypertension, and congestive heart failure. |
Metabolic Disorders |
Exelixis |
P1 |
| ME-143 |
Captisol-enabled |
Anti-tumors |
Marshall Edwards |
Phase I |
| CUDC-101 (IV) |
Captisol- enabled IV HDAC / EGFR / Her2 Inhibitor
|
Oncology |
Curis, Inc. |
Phase I |
| CXCR4 (inflammation) |
CXCR4 AntagonistA small molecule CXCR4 antagonist is being developed to treat Glioblastoma Multiforme (GBM). |
Inflammation |
Proximagen |
Preclinical |
| Undisclosed |
Captisol-enabled CNS therapeutics |
CNS |
SAGE |
Preclinical |
More than 25 other undisclosed Captisol-enabled® programs with partners.